Skip to main content
MRMD
OTC Life Sciences

MariMed Reports Improved Q1 Profitability with 44% Adjusted EBITDA Growth

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Positive
Importance info
7
Price
$0.084
Mkt Cap
$33.509M
52W Low
$0.064
52W High
$0.23
52W Position info
31% above low
Off High info
63% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

MRMD sits 31% above its 52-week low of $0.064.

Summary

MariMed Inc. announced its first-quarter 2026 financial results, showing improved profitability with a 44% increase in Adjusted EBITDA and a narrower net loss compared to the prior year.


Key Events · Earnings and Guidance · MRMD

  • Adjusted EBITDA Surges

    Non-GAAP Adjusted EBITDA increased by 44% year-over-year to $3.6 million in Q1 2026, up from $2.5 million in Q1 2025, with the Adjusted EBITDA margin expanding to 9% from 7%.

  • Net Loss Narrows

    The GAAP net loss improved to $(3.8) million in Q1 2026, compared to a net loss of $(5.5) million in the same period last year.

  • Revenue Growth

    Revenue for the first quarter of 2026 grew modestly by 4.2% to $39.5 million, up from $37.9 million in Q1 2025.

  • Debt Restructuring Highlighted

    The company highlighted its March 2, 2026, restructuring of $14.725 million in Series B Convertible Preferred Stock obligations, which extended the weighted average maturity to 4.6 years and enhanced liquidity.


Analysis · MRMD · Life Sciences

MariMed Inc. reported a significant 44% year-over-year increase in Adjusted EBITDA and a reduced net loss for Q1 2026. This operational improvement is crucial for the micro-cap company, especially following its recent debt restructuring and ongoing efforts to strengthen its financial position in a challenging industry.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $33.5M. The 52-week trading range was $0.06 to $0.23. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MRMD - Latest Insights

MRMD
Nov 12, 2026, 5:43 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $0.075
Real-time Price: $0.0471 info
Change: -$0.0279 (-37%) info
Market Cap: $19.122M info
MRMD
Nov 11, 2026, 5:01 PM EST
Source: Reuters
Importance Score:
7
Price at Filing: $0.0745
Real-time Price: $0.0471 info
Change: -$0.0274 (-37%) info
Market Cap: $19.122M info
MRMD
Oct 29, 2026, 4:13 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $0.053
Real-time Price: $0.0471 info
Change: -$0.0059 (-11%) info
Market Cap: $19.122M info
MRMD
Sep 22, 2026, 4:42 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $0.0732
Real-time Price: $0.0471 info
Change: -$0.0261 (-36%) info
Market Cap: $19.122M info
MRMD
Sep 11, 2026, 4:06 PM EDT
Filing Type: PRE 14A
Importance Score:
7
Price at Filing: $0.0788
Real-time Price: $0.0471 info
Change: -$0.0317 (-40%) info
Market Cap: $19.122M info